TMC Life Sciences Bhd (0101) - Net Assets
Based on the latest financial reports, TMC Life Sciences Bhd (0101) has net assets worth RM862.53 Million MYR (≈ $216.55 Million USD) as of February 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM1.11 Billion ≈ $278.68 Million USD) and total liabilities (RM247.47 Million ≈ $62.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is TMC Life Sciences Bhd's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM862.53 Million |
| % of Total Assets | 77.71% |
| Annual Growth Rate | 16.23% |
| 5-Year Change | 8.03% |
| 10-Year Change | 34.49% |
| Growth Volatility | 41.86 |
TMC Life Sciences Bhd - Net Assets Trend (2006–2025)
This chart illustrates how TMC Life Sciences Bhd's net assets have evolved over time, based on quarterly financial data. Check 0101 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for TMC Life Sciences Bhd (2006–2025)
The table below shows the annual net assets of TMC Life Sciences Bhd from 2006 to 2025. For live valuation and market cap data, see 0101 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | RM853.04 Million ≈ $214.17 Million |
-3.94% |
| 2024-08-31 | RM888.03 Million ≈ $222.96 Million |
+3.03% |
| 2023-08-31 | RM861.96 Million ≈ $216.41 Million |
+4.18% |
| 2022-08-31 | RM827.39 Million ≈ $207.73 Million |
+4.78% |
| 2021-08-31 | RM789.62 Million ≈ $198.25 Million |
+2.27% |
| 2020-08-31 | RM772.12 Million ≈ $193.85 Million |
+1.30% |
| 2019-08-31 | RM762.24 Million ≈ $191.37 Million |
+2.97% |
| 2018-08-31 | RM740.24 Million ≈ $185.85 Million |
+3.61% |
| 2017-08-31 | RM714.42 Million ≈ $179.37 Million |
+12.64% |
| 2016-08-31 | RM634.26 Million ≈ $159.24 Million |
+110.22% |
| 2015-08-31 | RM301.71 Million ≈ $75.75 Million |
+122.84% |
| 2014-08-31 | RM135.39 Million ≈ $33.99 Million |
+3.11% |
| 2013-08-31 | RM131.31 Million ≈ $32.97 Million |
+9.25% |
| 2012-08-31 | RM120.19 Million ≈ $30.18 Million |
+81.99% |
| 2011-08-31 | RM66.04 Million ≈ $16.58 Million |
-36.21% |
| 2009-08-31 | RM103.54 Million ≈ $25.99 Million |
-9.19% |
| 2008-08-31 | RM114.02 Million ≈ $28.63 Million |
+51.35% |
| 2007-08-31 | RM75.33 Million ≈ $18.91 Million |
+53.85% |
| 2006-08-31 | RM48.97 Million ≈ $12.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TMC Life Sciences Bhd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 941.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM227.06 Million | 26.62% |
| Common Stock | RM625.99 Million | 73.38% |
| Total Equity | RM853.04 Million | 100.00% |
TMC Life Sciences Bhd Competitors by Market Cap
The table below lists competitors of TMC Life Sciences Bhd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
$205.55 Million |
|
Samara Asset Group
F:SRAG
|
$205.59 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
$205.77 Million |
|
HomeChoice Investments Ltd
JSE:HIL
|
$205.79 Million |
|
Vakif Gayrimenkul Yatirim Ortakligi AS
IS:VKGYO
|
$205.54 Million |
|
Datawalk SA
WAR:DAT
|
$205.53 Million |
|
Circio Holding ASA
OL:CRNA
|
$205.50 Million |
|
Alpha Teknova Inc
NASDAQ:TKNO
|
$205.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TMC Life Sciences Bhd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 888,034,000 to 853,043,000, a change of -34,991,000 (-3.9%).
- Net income of 3,606,000 contributed positively to equity growth.
- Dividend payments of 38,616,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,316,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM3.61 Million | +0.42% |
| Dividends Paid | RM38.62 Million | -4.53% |
| Other Comprehensive Income | RM-1.32 Million | -0.15% |
| Other Changes | RM1.33 Million | +0.16% |
| Total Change | RM- | -3.94% |
Book Value vs Market Value Analysis
This analysis compares TMC Life Sciences Bhd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.76x to 0.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-08-31 | RM0.27 | RM0.47 | x |
| 2007-08-31 | RM0.40 | RM0.47 | x |
| 2008-08-31 | RM0.20 | RM0.47 | x |
| 2009-08-31 | RM0.16 | RM0.47 | x |
| 2011-08-31 | RM0.11 | RM0.47 | x |
| 2012-08-31 | RM0.14 | RM0.47 | x |
| 2013-08-31 | RM0.11 | RM0.47 | x |
| 2014-08-31 | RM0.11 | RM0.47 | x |
| 2015-08-31 | RM0.31 | RM0.47 | x |
| 2016-08-31 | RM0.34 | RM0.47 | x |
| 2017-08-31 | RM0.38 | RM0.47 | x |
| 2018-08-31 | RM0.41 | RM0.47 | x |
| 2019-08-31 | RM0.44 | RM0.47 | x |
| 2020-08-31 | RM0.44 | RM0.47 | x |
| 2021-08-31 | RM0.45 | RM0.47 | x |
| 2022-08-31 | RM0.47 | RM0.47 | x |
| 2023-08-31 | RM0.49 | RM0.47 | x |
| 2024-08-31 | RM0.51 | RM0.47 | x |
| 2025-08-31 | RM0.49 | RM0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TMC Life Sciences Bhd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.04%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.33x
- Recent ROE (0.42%) is below the historical average (0.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 18.72% | 36.81% | 0.41x | 1.24x | RM4.27 Million |
| 2007 | 12.38% | 29.85% | 0.33x | 1.25x | RM1.80 Million |
| 2008 | 3.14% | 9.21% | 0.23x | 1.49x | RM-7.83 Million |
| 2009 | -8.51% | -18.65% | 0.27x | 1.68x | RM-19.15 Million |
| 2011 | -53.02% | -43.44% | 0.55x | 2.21x | RM-41.62 Million |
| 2012 | -5.34% | -10.36% | 0.40x | 1.28x | RM-18.44 Million |
| 2013 | 8.44% | 15.34% | 0.46x | 1.19x | RM-2.05 Million |
| 2014 | 4.77% | 7.47% | 0.53x | 1.22x | RM-7.08 Million |
| 2015 | 3.29% | 9.62% | 0.30x | 1.13x | RM-20.25 Million |
| 2016 | 2.35% | 11.66% | 0.18x | 1.10x | RM-48.53 Million |
| 2017 | 3.64% | 17.16% | 0.20x | 1.08x | RM-45.41 Million |
| 2018 | 3.75% | 16.44% | 0.21x | 1.08x | RM-46.23 Million |
| 2019 | 2.74% | 10.73% | 0.23x | 1.11x | RM-55.30 Million |
| 2020 | 2.06% | 8.65% | 0.19x | 1.23x | RM-61.28 Million |
| 2021 | 2.57% | 10.08% | 0.19x | 1.34x | RM-58.71 Million |
| 2022 | 5.00% | 16.98% | 0.22x | 1.37x | RM-41.35 Million |
| 2023 | 4.55% | 12.60% | 0.26x | 1.37x | RM-46.94 Million |
| 2024 | 4.58% | 11.73% | 0.29x | 1.34x | RM-48.16 Million |
| 2025 | 0.42% | 1.04% | 0.31x | 1.33x | RM-81.70 Million |
Industry Comparison
This section compares TMC Life Sciences Bhd's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $4,921,137,690
- Average return on equity (ROE) among peers: 6.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TMC Life Sciences Bhd (0101) | RM862.53 Million | 18.72% | 0.29x | $205.54 Million |
| Optimax Holdings Sdn Bhd (0222) | $16.34 Million | 45.23% | 1.46x | $71.61 Million |
| Cengild Medical Berhad (0243) | $111.30 Million | 9.95% | 0.19x | $40.78 Million |
| DC HEALTHCARE HOLDINGS BERHAD (0283) | $44.74 Million | -43.92% | 1.41x | $30.02 Million |
| ALPHA (0303) | $28.36 Million | 8.70% | 1.64x | $311.01 Million |
| IHH Healthcare Bhd (5225) | $27.28 Billion | 6.83% | 0.67x | $18.86 Billion |
| KPJ Healthcare Bhd (5878) | $2.05 Billion | 10.31% | 1.92x | $3.53 Billion |
About TMC Life Sciences Bhd
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara hospital located in prime alcove of Kota Damansara. It is involved in providing multi-disciplinary tertiary care, traditional and complementary, obstetrics and gynaecology, fertility services; operating fertility centres and women clinics; propert… Read more